Literature DB >> 3184335

Group A meningococcal carriage in travelers returning from Saudi Arabia.

P S Moore1, L H Harrison, E E Telzak, G W Ajello, C V Broome.   

Abstract

In August 1987, an outbreak of group A meningococcal meningitis occurred during the annual pilgrimage to Mecca, Saudi Arabia, resulting in an attack rate among American pilgrims of 640 per 100,000. To determine risk factors for carriage, throat cultures were taken from passengers arriving on four consecutive flights from Saudi Arabia to the United States. Pilgrims were more likely to be group A meningococcal carriers than were nonpilgrims (relative risk, 11.1; 95% confidence interval, 3.7 to 33.1). Smoking, crowding, and meningococcal vaccination were not significantly associated with group A carriage. Pilgrims complaining of recent fever or sore throat, however, were more likely to be group A carriers, consistent with previous reports linking carriage and disease to preceding viral infections. Serogrouping of invasive meningococcal isolates can be used to monitor for indigenous transmission of this unusual strain in the United States, and we recommend routine vaccination of pilgrims to prevent future outbreaks of meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3184335

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  30 in total

1.  Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis.

Authors:  P Zhu; A van der Ende; D Falush; N Brieske; G Morelli; B Linz; T Popovic; I G Schuurman; R A Adegbola; K Zurth; S Gagneux; A E Platonov; J Y Riou; D A Caugant; P Nicolas; M Achtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

2.  The 1998 Senegal epidemic of meningitis was due to the clonal expansion of A:4:P1.9, clone III-1, sequence type 5 Neisseria meningitidis strains.

Authors:  P Nicolas; G Raphenon; M Guibourdenche; L Decousset; R Stor; A B Gaye
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 3.  Global epidemiology of meningococcal disease.

Authors:  B Schwartz; P S Moore; C V Broome
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

4.  Spatial dynamics of meningococcal meningitis in Niger: observed patterns in comparison with measles.

Authors:  N Bharti; H Broutin; R F Grais; M J Ferrari; A Djibo; A J Tatem; B T Grenfell
Journal:  Epidemiol Infect       Date:  2011-10-05       Impact factor: 2.451

5.  Characterization of Neisseria meningitidis serogroup A strains from an outbreak in France by serotype, serosubtype, multilocus enzyme genotype and outer membrane protein pattern.

Authors:  J Y Riou; D A Caugant; R K Selander; J T Poolman; M Guibourdenche; E Collatz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-05       Impact factor: 3.267

Review 6.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

7.  Phenotypic and molecular characterization of invasive serogroup W135 Neisseria meningitidis strains from 1990 to 2005 in Brazil.

Authors:  Ana Paula S Lemos; Lee H Harrison; Melina Lenser; Claudio T Sacchi
Journal:  J Infect       Date:  2010-01-06       Impact factor: 6.072

8.  Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.

Authors:  Jean-François Aguilera; Anne Perrocheau; Christine Meffre; Susan Hahné
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

9.  Persistence of W135 Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts.

Authors:  Annelies Wilder-Smith; Timothy M S Barkham; Sindhu Ravindran; Arul Earnest; Nicholas I Paton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

10.  Meningococcal disease and climate.

Authors:  Helena Palmgren
Journal:  Glob Health Action       Date:  2009-11-11       Impact factor: 2.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.